Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2022 | Evaluation of sNfL in MS patients with NEDA-3

Virginia Meca-Lallana, MD, La Princesa University Hospital, Madrid, Spain, describes an observational study evaluating serum neurofilament light chain (sNfL) levels in patients with multiple sclerosis (MS) who achieve no evidence of disease activity-3 (NEDA-3) status. These patients have no MRI activity, no clinical relapses, and no disability worsening. Dr Meca-Lallana explains the theory that higher NfL levels could predict short-term neuroinflammatory activity and long-term MS progression. All 48 patients exhibited elevated levels of NfL, consistent with prior studies. The study also found that the longer the patient had MS, the lower the level of NfL. There were higher levels of NfL in patients using moderate efficacy treatments, compared to those on highly effective treatments. Dr Meca-Lallana notes that these results are preliminary and a longer study will be carried out to establish more robust conclusions. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.